Profund Advisors LLC Takes $1.06 Million Position in Stoke Therapeutics, Inc. $STOK

Profund Advisors LLC acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,388 shares of the company’s stock, valued at approximately $1,060,000. Profund Advisors LLC owned about 0.06% of Stoke Therapeutics at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Generali Investments Management Co LLC purchased a new stake in shares of Stoke Therapeutics during the third quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after buying an additional 658 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Stoke Therapeutics during the third quarter valued at $150,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on STOK shares. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Guggenheim started coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Needham & Company LLC boosted their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings downgraded shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Arthur Tzianabos sold 4,355 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the transaction, the insider owned 31,339 shares in the company, valued at approximately $1,253,560. This represents a 12.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88. Following the completion of the transaction, the chief financial officer owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. This trade represents a 18.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 69,699 shares of company stock valued at $2,526,714 over the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $29.67 on Friday. The company has a market capitalization of $1.85 billion, a PE ratio of -10.56 and a beta of 1.20. The company has a fifty day moving average of $33.36 and a 200 day moving average of $31.94. Stoke Therapeutics, Inc. has a 1 year low of $9.09 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. Research analysts expect that Stoke Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.